Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy - Wikidata - wikimedia - TriplyDB

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

http://www.wikidata.org/entity/Q26993238

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Targeted Therapies in Adult B-Cell Malignancies Trial Watch: Adoptive cell transfer for oncological indications Chloroquine and hydroxychloroquine for cancer therapy Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy Trial watch: Dendritic cell-based anticancer therapy Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy Trial Watch-Oncolytic viruses and cancer therapy Trial Watch-Immunostimulation with cytokines in cancer therapy Trial Watch: Proteasomal inhibitors for anticancer therapy Trial Watch: Toll-like receptor agonists in oncological indications.Trial watch: Immunostimulatory cytokines in cancer therapy.Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.Novel immune checkpoint blocker approved for the treatment of advanced melanoma A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients Selection strategies for anticancer antibody discovery: searching off the beaten path.Trial watch: Naked and vectored DNA-based anticancer vaccines A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.Doubling the blockade for melanoma immunotherapy Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure.Prevention of breast cancer by RANKL/RANK blockade.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy New approaches to selectively target cancer-associated matrix metalloproteinase activity.Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Impact of the immune system and immunotherapy in colorectal cancer.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Active Immunotherapy of Cancer.Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?Beyond the margins: real-time detection of cancer using targeted fluorophores.A Primer for Oncoimmunology (Immunooncology).T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.

P2860

Q26769884-B2AC393B-CC88-4908-B242-0A4911E6DDF4 Q26783195-F25B8FCC-E506-4C5B-973B-71A52EEF120A Q26785545-DA06A791-F9F0-44CA-8F9E-F04ABB2274DD Q26827797-AAA8BFD7-1657-49F3-BE6A-11720AF0450D Q26866236-A9173D90-FAA7-42F1-A979-8F355C2D2DAD Q26996518-FBC3EAC6-3E63-465B-BCF4-3FD03A017AAC Q27004011-5C87E7CE-D8FE-47A0-ACF8-35F95619FB8A Q27024047-3B5708D8-3238-4684-891F-356A58C0DB2E Q28067939-34BBD528-8A58-4DCA-897D-50A8EAA7C970 Q28072347-CD90D940-375F-4340-BA6D-62B2CA3C225B Q28078725-39CA5986-FCB6-4975-A04D-64E7AE22584B Q28082910-CA6701D4-061C-4CD3-BE2E-055F8854053A Q33878578-52A575B7-435D-4AFA-9550-0C2C78E954F0 Q33880165-B494D8E5-2C84-412E-ACA9-126899602ACE Q34408337-016F23AF-3E6A-4E9F-9907-B47E6ECCBE16 Q34936394-1886D6E7-4DE7-4320-BD01-38D68074A77D Q35142620-78FFDF10-B46F-4173-804B-95113FDC3BA7 Q35282416-D2D56EA8-05E7-4983-9F13-BDDCFD69195B Q35544786-CABC1C1B-ED93-4D07-B663-EA4163D83825 Q35589427-97CDCB80-CD95-49B0-AEE0-D30A2748A1E7 Q35798986-A43EA638-F341-45A5-B999-F3DEF23332E3 Q36214463-C86143E2-7CC3-436A-BE51-99BDC2C13581 Q36597356-DC2499B8-32DD-4384-B73F-9A5413C1BF3E Q36781992-5D14C574-90BD-40B5-96A4-0A911D63FA71 Q37457322-CE66D367-EC3E-4F5B-B9F6-9D6C6947A4D1 Q37652790-C1D108FF-7393-4EE3-A35A-191D9C0DCE34 Q38261141-5756841C-28DA-4C42-9FBD-7BD624D02A20 Q38283536-0B1EA69F-BE2F-4257-928F-EA83BBA21CA3 Q38391533-6F71A17D-7411-4895-92BC-035151CA78C7 Q38398877-1AFB4E52-DED9-4568-B1E2-D7DDDBF9C9E1 Q38447992-FDFD176E-148B-4E96-A8C7-E7BCD350C530 Q38635419-AFD4DF00-DE6A-4797-B4F0-B07EB1FF41CD Q38963228-FECDFD8E-449D-4902-8C35-9BB315FF16BE Q39091749-5745183C-0F22-4DEC-B765-3059FA8F85BE Q39387761-0C5494D8-9D16-4F7C-A86C-2476EBE2F80B Q41127889-AFB0A352-4C61-42EB-81CD-8E2B1FF2EB69 Q41592435-FE0D66B1-EEF1-440A-A999-2624338B4C0F Q42291172-7B206851-CEEB-402B-9A0E-3A31E31AA32C Q42558833-D6F97D18-ECAD-4CEE-86B5-9D1D84150ACA Q51738393-34C76CEC-ECA2-43F5-99DE-FC8FDA319D4F

P2860

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

http://www.wikidata.org/entity/Q26993238

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@ast

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@en

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@nl

type

label

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@ast

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@en

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@nl

prefLabel

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@ast

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@en

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@nl

P1433

Q26993238-721155EB-47C7-47C1-A24F-6DEA8EC8F297

P1476

Q26993238-605D1C02-9E1B-4BF9-ABA6-4ADB6B9B5700

P2860

Q26993238-034325D2-A7F5-42FA-9A19-72B2A39F3910

Q26993238-036412FA-7FF1-4251-A456-239C4F9B1E4C

Q26993238-03C7CF08-B824-4F99-8992-F26CF169926C

Q26993238-04015FEA-CD50-45CE-935D-6DF616525495

Q26993238-049CE7B4-BF58-44F2-AFF6-D40683D5C9F8

Q26993238-05A81B91-A2A8-4169-82DD-483012AC83F7

Q26993238-0603AEC9-E0D8-44D9-B815-BAD9493B31EB

Q26993238-0847E119-8B55-4385-B951-0925BCFC496F

Q26993238-0AACFF17-67E4-4AB3-B8E4-77A8E29ED7F2

Q26993238-0C3EC764-8362-4566-A97F-31F86D15613D

P304

Q26993238-4E139DC6-8475-4C2B-955C-AEB809D0204C

P31

Q26993238-6E3A5B4A-AB1C-4553-A0F7-3D9E05CEF116

P356

Q26993238-46B0EA69-6AE7-42F8-B08F-4BC2F8377B92

P407

Q26993238-C58331D6-A627-4C3B-B174-29132A11FACE

P433

Q26993238-F4D475BB-F943-4CB2-AF78-4F2F71C7583B

P478

Q26993238-573781D6-18F3-4147-8E8D-109AB7AF30C5

P50

Q26993238-19E0A24F-87D9-49A0-B6FD-BEB1FA8EC3D6

Q26993238-25FA4987-E3DD-4A27-BB96-C3D645CBF08F

Q26993238-38D35897-D1F9-495F-AF00-2A096BD7E40A

Q26993238-5BE93302-7243-462A-9EC4-49E10E7B561F

Q26993238-69D2CDF7-AAD8-469C-A4EF-07020A1A6384

Q26993238-96698D36-C1C0-4DFE-8187-80FF81FFBF52

Q26993238-C16E5227-E535-4E45-BD12-9EA8B6E1683D

Q26993238-EC2CDFCA-0B95-407C-9D6E-385238CC3629

P577

Q26993238-E96A09E6-AC3A-4342-8E9E-0204F028AA0B

P5875

Q26993238-86ACF393-A4EE-4373-8630-7D79471A2357

P698

Q26993238-FA0515B4-D829-43E0-8306-983166BC3F17

P921

Q26993238-281A443D-407A-478F-83AF-FF888F758836

P932

Q26993238-823F3B50-2A2B-411B-B807-1C43C2E3993D

P356

P1433

P1476

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

@en

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Continuous cultures of fused cells secreting antibody of predefined specificity

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule

Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

P304

e27048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.27048

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Galluzzi

Laurence Zitvogel

Alexander Eggermont

Fernando Aranda

Catherine Sautès-Fridman

Erika Vacchelli

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261795530

http://www.w3.org/2001/XMLSchema#string

P698

24605265

http://www.w3.org/2001/XMLSchema#string

P921

P932

3937194

http://www.w3.org/2001/XMLSchema#string